JUMP REPORT
NOVAVAX (NVAX)
EARNINGS RELEASE - AUGUST 10 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.42/share REV: 39.58/M
___________________________________________________________
LAST QTR: EPS: -.70/share ACTUAL: -.58/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 1.35/share REV: 234.3/M
____________________________________________________________
FULL YR: EPS: 7.97/share REV: 1,100/M
____________________________________________________________
BEAT/MISS RECORD: 35% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 83.4, -12.9, 7.77
EXPECTED JUMP MOVE THIS QUARTER: 15-20%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before tradin
Links To Latest News and Headlines
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and opposed proposals related to executive compensation, weeks after pushing for a board shakeup at the COVID-19 vaccine maker. Shah Capital, the biotech’s third-largest shareholder with a near 7.5% stake, reiterated the company was “undervalued and continues to suffer from poor profitability”. The hedge fund had previously said it planned to put forward two of its own candidates for Novavax’s board, but was unable to meet the requirements to do so on time.
(Reuters) -Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and opposed proposals related to executive compensation, weeks after pushing for a board shakeup at the COVID-19 vaccine maker. Shah Capital, the biotech’s third-largest shareholder with a near 7.5% stake, reiterated the company was “undervalued and continues to suffer from poor profitability”. The hedge fund had previously said it planned to put forward two of its own candidates for Novavax’s board, but was unable to meet the requirements to do so on time.
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and proposals related to executive compensation, ramping up its efforts for a board shakeup at the COVID-19 vaccine maker. Shah Capital, which currently owns a near 7.5% stake in Novavax and is its third-largest shareholder, reiterated that the company was “undervalued and continues to suffer from poor profitability”. Novavax last year had raised doubts about its ability to remain in business, hurt by manufacturing snags and regulatory hurdles that delayed the entry of its protein-based vaccine to the market.
Highlights Novavax’s Massive Untapped Value That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined Stockholder Value Calls for Fresh Perspectives in the Boardroom to Restore Investor Confidence in the Company Files Preliminary Proxy and Urges Stockholders to Vote AGAINST The Re-Election of all Class II Directors and AGAINST The Approval of Three of the Company’s Other Proposals at the Annual Meeting RALEIGH, N.C., Ma
In the latest trading session, Novavax (NVAX) closed at $4.33, marking a +0.93% move from the previous day.
StockJumpers analysis and trade plans are finalized and uploaded generally one house before market cloase (3PM EST) for most events unless noticed.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
Members who are too busy to manual trade can use Trade Assist. For more information visit here
Avg Daily Volume: 8,831,772 Market Cap: 5.65B Sector: Healthcare Short Interest: 13.87 |
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.